Effects of anlotinib combined with second-line chemotherapy on the levels of immune cells and inflammatory factors and the curative effects in patients with advanced non-small cell lung cancer

Abstract

Objective: To investigate the effects of anlotinib combined with second-line chemotherapy on the levels of immune cells and inflammatory factors and the curative effects in patients with advanced non-small cell lung cancer. Methods: A total of 106 patients with advanced non-small cell lung cancer were selected from November 2020 to March 2022 for clinical and hospital treatment as the research subjects. The patients were divided into a control group (n = 53) and an observation group (n = 53). The control group was treated with second-line single-agent chemotherapy regimens, and the observation group was treated with second-line combination chemotherapy including anlotinib. The prognostic effect, adverse reactions, levels of immune cells and inflammatory factors before and after treatment were observed and compared between the two groups. Results: There were no statistically significant differences in sex, age, lesion diameter, BMI or other general data between the two groups (P > 0.05), indicating comparability. The clinical efficacy of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P<0.05). Before treatment, the levels of CD4+ and CD4+/CD8+ in the observation group were significantly higher than those in the control group, and the differences were statistically significant (P < 0.05). . After treatment, the levels of IL-6, IL-8, IL-10 and TNF-α in the observation group were lower than those in the control group, and the difference was statistically significant (P < 0.05). There were no significant differences in the incidence of nausea and vomiting, liver function damage, alopecia or leukopenia between the 2 groups (P > 0.05). Conclusion: Anlotinib combined with second-line chemotherapy has positive effects on the levels of immune cells and inflammatory factors in patients with advanced non-small cell lung cancer, which can reduce immunosuppression and benefit prognosis